| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
|
|---|
| Outline of Final Research Achievements |
1) Peripheral neuropathy caused by bortezomib was reduced in patients receiving a concomitant drug X1 in FAERS data. When the effects were investigated in mice, an intrathecal injection of X1 reduced hyperalgesia caused after chronic treatment with bortezomib. Bortezomib caused dedifferentiation of Schwann cells leading to the activation of macrophages.
2) Peripheral neuropathy caused by paclitaxel was reduced in patients receiving another concomitant drug X2 in FAERS data. When mice had been chronically received paclitaxel, an intravenous injection with X2 acutely attenuated the pain responses in mice. From in vitro study, X2 may exert its action by removing proinflammatory substance in the periphery.
|
